Climara Pro

relieves symptoms associated with menopause such as hot flashes. It comes as a patch. Rotate application sites and avoid the waistline.

Climara Pro Overview

Updated: 

Climara Pro is a prescription medication used after menopause to reduce moderate to severe hot flashes and help reduce your chances of getting osteoporosis (thin weak bones).

Climara Pro contains two hormones, estradiol and levonorgestrel, and belongs to a group of drugs called estrogen and progestin combinations. Climara Pro works as a hormone replacement to relieve issues caused by hormonal changes. 

Climara Pro comes in a patch form and is usually applied to the skin once weekly. 

Common side effects of Climara Pro include reactions at the application site, vaginal bleeding, and breast pain. 

Patient Ratings for Climara Pro

How was your experience with Climara Pro?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking Climara Pro?

What are you taking Climara Pro for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did Climara Pro work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend Climara Pro to a friend?

Manufacturer

Estradiol and Levonorgestrel

For more information on this medication choose from the list of selections below.

Climara Pro Drug Class

Climara Pro is part of the drug class:

Climara Pro FDA Warning

Warning: Cardiovascular disorders, breast cancer, endometrial cancer, and probable dementia

Estrogen Plus Progestin Therapy

Cardiovascular Disorders and Probable Dementia

Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.

The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogen (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo.

The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

Breast Cancer

The WHI estrogen plus progestin substudy also demonstrated an increased risk of invasive breast cancer.

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

Estrogen-Alone Therapy

Endometrial Cancer

There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

Cardiovascular Disorders and Probable Dementia

Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia.

The WHI estrogen-alone substudy reported increased risks of stroke and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone, relative to placebo.

The WHIMS estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.

In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens.

Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment.